$SUPN (Supernus Pharmaceuticals, Inc.)

$SUPN {{ '2016-06-03T05:26:48+0000' | timeago}} • Announcement

Pharma company $SUPN said a sixth patent has been issued by the United States Patent and Trademark Office on May 31 covering Oxtellar XR, a once-daily extended-release oxcarbazepine product. Oxtellar XR is an antiepileptic drug indicated for adjunctive therapy in treating partial seizures in adults and in children 6-17 years of age.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$GSK {{ '2017-07-21T15:28:58+0000' | timeago}} • Announcement

$GSK and $INVA announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta in patients with controlled asthma on an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA).

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$ISRG {{ '2017-07-21T12:26:16+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ISRG {{ '2017-07-20T20:21:13+0000' | timeago}} • Announcement

In 2Q17, $ISRG's service revenue rose 11% to $142MM while instrument and accessory revenue jumped 17% to $398MM. Intuitive Surgical ended the second quarter with $3.4Bil in cash, cash equivalents, and investments.

$ISRG {{ '2017-07-20T20:16:13+0000' | timeago}} • Announcement

In 2Q17, revenue for $ISRG jumped 13% to $756MM while net income soared 20% to $222MM or $5.77 per diluted share. Non-GAAP net income was $228MM or $5.95 per diluted share, with systems revenue increased by approximately 7% to $216MM.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$MRK {{ '2017-07-20T14:29:27+0000' | timeago}} • Announcement

$MRK announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its 100 units/mL insulin glargine injection, a follow-on biologic basal insulin in a pre-filled dosing device.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$DGX {{ '2017-07-18T13:54:10+0000' | timeago}} • Announcement

Medical diagnostics firm $DGX has completed the acquisition of laboratory businesses Med Fusion and Clear Point. They form the basis for Quest’s first national center of excellence in precision diagnostics for oncology. The company is now a preferred provider to several organizations that are formerly owners of one or both of the acquired entities.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$DEPO {{ '2017-07-13T12:48:44+0000' | timeago}} • Announcement

Pharma company $DEPO is seeking to refinance its existing $375MM principal amount of privately placed secured senior notes. The notes are due in 2022. The terms of refinancing are subject to various factors, including satisfaction of customary closing conditions.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$MRK {{ '2017-07-06T12:50:08+0000' | timeago}} • Announcement

Pharma company $MRK will present its HIV portfolio and pipeline at the 9th IAS Conference on HIV Science. The presentations include late-breaker abstracts from two phase-3 pivotal clinical trials and a phase-1 study of MK-8591, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

$MRK {{ '2017-07-05T22:11:39+0000' | timeago}} • Announcement

$MRK said the US FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. The FDA has determined that the risks of KEYTRUDA outweigh any potential benefit for patients with multiple myeloma.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
SUPN (Supernus Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
DEPO (DepoMed Inc.)
Tuesday, May 9 2017 - 8:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
DGX (Quest Diagnostics Inc.)
Thursday, April 20 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
ISRG (Intuitive Surgical, Inc.)
Tuesday, April 18 2017 - 8:30pm
PTX (Pernix Therapeutics Holdings, Inc.)
Tuesday, March 28 2017 - 8:30pm
DRRX (DURECT Corporation)
Tuesday, March 14 2017 - 8:30pm
ATRS (Antares Pharma Inc.)
Tuesday, March 14 2017 - 12:30pm
SUPN (Supernus Pharmaceuticals, Inc.)
Wednesday, March 1 2017 - 2:00pm

AlphaGraphics you may like